• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids

byConstance Wu
February 14, 2020
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

Linzagolix significantly reduces heavy menstrual bleeding in women with uterine fibroids

Relugolix combination therapy is efficacious for endometriosis-associated pain

#VisualAbstract Menopausal hormone therapy was not associated with risk of cutaneous melanoma

1. In this pair of identical phase 3 trials involving premenopausal women with uterine fibroids, both elagolix with and without add-back therapy was more effective in reducing heavy menstrual bleeding than placebo.

2. Significant decreases in bone mineral density were observed in the group that received elagolix without add-back therapy, but the hypoestrogenic effects of elagolix were successfully attenuated in the treatment group that also received add-back therapy.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Uterine fibroids can cause heavy menstrual bleeding along with a host of symptoms including pelvic pain, gastrointestinal upset, and infertility. Current non-surgical options including progestins, tranexamic acid, and uterine-artery embolization have demonstrated only limited effectiveness and can carry long-lasting hypoestrogenic side effects such as decreased bone density and vasomotor symptoms. Elagolix is a reversible nonpeptide gonadotropin-releasing hormone (GnRH) antagonist that is currently approved for endometriosis-associated pain and was also efficacious in reducing menstrual bleeding in a phase 2b trial involving women with uterine fibroids. This study combined two identical phase 3 trials with the objective of assessing the safety and efficacy of elagolix as well as the impact of add-back hormone therapy on hypoestrogenic effects. Menstrual blood loss was found to be significantly lower in women who received elagolix with add-back therapy than in those who received placebo, with suppression of bleeding in the final month in over half of the group. Patients who received elagolix without add-back therapy also reaped these benefits but faced greater decreases from baseline in bone mineral density. Most adverse events in both elagolix groups were mild or moderate, the most common being hot flushes, and all serious events were resolved by the end of the trial.

Click here to read the study in NEJM

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: elagolixestradiolestrogenfibroidgonadotropinnorethindroneuterine bleeding
Previous Post

Despite regular visits to pediatrician, few adolescent men having sex with men tested for HIV

Next Post

#VisualAbstract: Teprotumumab for the Treatment of Active Thyroid Eye Disease

RelatedReports

Simvastatin associated with slowed fibroid growth in mice
Chronic Disease

Linzagolix significantly reduces heavy menstrual bleeding in women with uterine fibroids

September 28, 2022
Chronic Disease

Relugolix combination therapy is efficacious for endometriosis-associated pain

June 30, 2022
#VisualAbstract Menopausal hormone therapy was not associated with risk of cutaneous melanoma
StudyGraphics

#VisualAbstract Menopausal hormone therapy was not associated with risk of cutaneous melanoma

July 22, 2021
Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial
Chronic Disease

Transdermal estrogen shows similar cardiovascular safety profile to traditional luteinizing hormone therapy in patients with prostate cancer

February 25, 2021
Next Post
#VisualAbstract: Teprotumumab for the Treatment of Active Thyroid Eye Disease

#VisualAbstract: Teprotumumab for the Treatment of Active Thyroid Eye Disease

Quick Take: Intravenous patient-controlled analgesia versus thoracic epidural analgesia after open liver surgery

Fibrinogen concentrate noninferior to cryoprecipitate after cardiac surgery in patients with excessive bleeding and hypofibrinogenemia

Delays in surgical intervention do not increase odds of appendiceal perforation

Thoracoscopic Talc Poudrage vs Talc Slurry via Chest Tube have similar outcomes

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • BNT162b2 booster is safe and reduces COVID-19 transmission in older adults
  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options